Hancock Whitney Corp Acquires 8,058 Shares of Cabot Co. (NYSE:CBT)

Hancock Whitney Corp boosted its stake in Cabot Co. (NYSE:CBT - Free Report) by 6.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 142,137 shares of the specialty chemicals company's stock after purchasing an additional 8,058 shares during the period. Hancock Whitney Corp owned about 0.26% of Cabot worth $12,979,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Pinebridge Investments L.P. boosted its position in shares of Cabot by 42.7% during the 4th quarter. Pinebridge Investments L.P. now owns 22,076 shares of the specialty chemicals company's stock worth $2,016,000 after purchasing an additional 6,604 shares in the last quarter. Hsbc Holdings PLC lifted its position in shares of Cabot by 359.1% during the 4th quarter. Hsbc Holdings PLC now owns 23,367 shares of the specialty chemicals company's stock worth $2,129,000 after buying an additional 18,277 shares in the last quarter. Stifel Financial Corp lifted its holdings in Cabot by 68.2% during the fourth quarter. Stifel Financial Corp now owns 75,717 shares of the specialty chemicals company's stock worth $6,914,000 after acquiring an additional 30,694 shares during the period. TD Waterhouse Canada Inc. purchased a new stake in shares of Cabot during the 4th quarter valued at $795,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Cabot by 225.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,617 shares of the specialty chemicals company's stock worth $787,000 after buying an additional 5,972 shares during the last quarter. 93.18% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on CBT. StockNews.com upgraded shares of Cabot from a "hold" rating to a "buy" rating in a research note on Thursday, April 17th. UBS Group lowered their price target on shares of Cabot from $93.00 to $83.00 and set a "neutral" rating for the company in a report on Monday, April 7th. JPMorgan Chase & Co. reduced their price target on Cabot from $105.00 to $85.00 and set an "underweight" rating on the stock in a report on Friday, February 21st. Finally, Mizuho dropped their price objective on Cabot from $122.00 to $110.00 and set an "outperform" rating for the company in a report on Tuesday, January 7th.

Cabot Stock Performance

NYSE CBT traded down $0.24 on Friday, hitting $79.27. 265,105 shares of the company traded hands, compared to its average volume of 390,756. Cabot Co. has a 52-week low of $73.63 and a 52-week high of $117.46. The company has a market capitalization of $4.30 billion, a price-to-earnings ratio of 10.53, a P/E/G ratio of 0.74 and a beta of 1.04. The business's 50 day moving average price is $81.93 and its 200-day moving average price is $93.69. The company has a current ratio of 2.00, a quick ratio of 1.29 and a debt-to-equity ratio of 0.72.

Cabot (NYSE:CBT - Get Free Report) last issued its earnings results on Monday, February 3rd. The specialty chemicals company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.74 by $0.02. Cabot had a return on equity of 26.79% and a net margin of 10.60%. Equities analysts expect that Cabot Co. will post 7.57 earnings per share for the current year.

Cabot Profile

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.